Leverage Robust LNP Analytical Methods to Generate Reproducible Data, Ensure Product Consistency & Accelerate Confident Regulatory Submissions to Support Genetic Medicine Approvals
Having announced brand-new acquisitions between AbbVie and Capstan Therapeutics as well as Eli Lilly & Co and Verve Therapeutics, celebrating the huge attraction of leveraging LNPs for cell and gene therapies. There was never a better time for you and your team to join the only industry-led forum turbocharging LNP characterization to advance these drug products towards approval.
The 3rd LNP Characterization & Analytical Development Summit provided unrivalled, in-depth technical insights into how to overcome critical challenges in assessing targeted LNP surface functionalization, evaluating encapsulation efficiency for multivalent formulations, and aligning analytical results with process performance to build more robust regulatory submissions.
Colleagues joined experts from Pfizer, Novo Nordisk, Prime Medicine, Tessera Therapeutics, GSK, Sanofi, Verve Therapeutics and more as they explored the cutting edge of LNP characterization and analytics. Don’t miss this opportunity to collaborate with the brightest minds shaping the future of LNP drug development in 2026.